D1 Like Dopamine Receptor Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neurons expressing D1-like dopamine receptors (D1R and D5R) constitute a major component of the dopaminergic system, mediating the rewarding and motor-activating effects of dopamine. These receptors are essential for movement initiation, reward processing, and cognitive function, and their dysfunction is central to Parkinson's disease and other neurodegenerative disorders.
| Property | Value |
|----------|-------|
| Category | Dopamine Receptor Neurons |
| Location | Striatum, cortex, hippocampus, limbic system |
| Receptor Types | D1R (DRD1), D5R (DRD5) |
| Signaling | Gs-coupled, cAMP elevation, PKA activation |
| Expression | Predominantly in medium spiny neurons of striatum |
| Taxonomy |
ID |
Name / Label |
| Cell Ontology (CL) |
CL:0000197 |
sensory receptor cell |
- Gene: DRD1
- Protein: 446 amino acids
- Expression: Highest in striatum (direct pathway MSNs)
- Affinity: High for dopamine, moderate for bromocriptine
- Gene: DRD5
- Protein: 475 amino acids
- Expression: Cortex, hippocampus, basal ganglia
- Affinity: Higher than D1 for dopamine
- Primary: Gs/olf → adenylyl cyclase → cAMP
- Downstream: PKA activation, DARPP-32 phosphorylation
- Effects: Increased neuronal excitability
- Desensitization: GRK phosphorylation, β-arrestin
- D1-D2 heteromers: Functional complexes with unique signaling
- D1-D5 interactions: Cooperative signaling
- Adenosine A2A-D1: Antagonistic interactions in striatum
- Striatum: 95% of D1R expressed in direct pathway MSNs
- Nucleus Accumbens: Shell and core involvement
- Olfactory tubercle: Reward processing
- Prefrontal cortex: Working memory circuits
- Motor cortex: Movement planning
- Anterior cingulate: Reward expectation
- Hippocampus: Memory consolidation
- ** Emotional learningAmygdala**:
- Bed nucleus of the stria terminalis: Stress response
- Thalamus: Sensory gating
- Hypothalamus: Neuroendocrine regulation
- Substantia nigra pars reticulata: Motor output
- Movement initiation: Direct pathway activation
- Movement suppression: Indirect pathway via D2R
- Motor learning: Skill acquisition
- Bradykinesia: Loss leads to parkinsonism
¶ Reward and Motivation
- Reward prediction: Phasic dopamine signals
- Motivated behavior: Approach motivation
- Reinforcement: Learning from rewards
- Addiction: Dopamine surge in substance abuse
- Working memory: Prefrontal cortex D1R
- Attention: Sustained attention
- Decision making: Value-based choices
- Cognitive flexibility: Set-shifting
- Planning: Goal-directed behavior
- Inhibition: Response inhibition
- Temporal discounting: Future rewards
- Pathology: Loss of dopaminergic neurons in SNc
- D1R changes: Upregulation in early PD (compensatory)
- D5R changes: Vulnerability to degeneration
- Motor symptoms: Loss of direct pathway activation
- Treatment: D1R agonists (rotigotine, apomorphine)
- Levodopa-induced dyskinesia: D1R overstimulation
- D1R polymorphisms: Genetic susceptibility factors
- Striatal degeneration: D1R-MSNs preferentially lost
- Motor symptoms: Chorea from D1-D2 imbalance
- Cognitive decline: Cortical D1R dysfunction
- Therapeutic target: D1R antagonists for dyskinesia
- Cognitive decline: D1R in prefrontal cortex
- Memory formation: Hippocampal D5R
- Attention deficits: Cortical D1R dysfunction
- Amyloid interaction: Aβ reduces D1R signaling
- Therapeutic potential: D1R modulators in development
- Cortical D1R: Loss of receptor binding
- Cognitive fluctuations: D1R dysfunction
- Parkinsonism: Nigrostriatal involvement
- Visual hallucinations: D1R in visual processing
- Executive dysfunction: Prefrontal D1R
- Behavioral variant: Limbic system D1R
- Language variants: Temporal cortex involvement
- D1R blockade: Antipsychotic-induced
- Reversal: D1R agonist therapy
- Tardive dyskinesia: D1R supersensitivity
- Parkinson's disease: D1R agonist therapy
- Parkinsonism-plus syndromes: Variable D1R involvement
- Dystonia: D1R mutations cause dystonia-parkinsonism
- Schizophrenia: D1R hypothesis of cognitive deficits
- Addiction: D1R in reward circuitry
- Depression: D1R in anhedonia
- ADHD: D1R polymorphisms
- D1R agonists: Rotigotine, apomorphine, bromocriptine
- D1R partial agonists: Aplindore
- D1R positive allosteric modulators: In development
- Gene therapy: AAV-D1R delivery
- Immunohistochemistry: Anti-D1R antibodies
- In situ hybridization: DRD1/DRD5 mRNA
- Radioligand binding: 3HSCH-23390
- Transgenic mice: D1R-Cre lines
- cAMP assays: Gs signaling measurement
- Electrophysiology: Current-clamp recordings
- Calcium imaging: DARPP-32 signaling
- Behavior: Rotarod, cylinder test
- Knockout mice: DRD1-/-, DRD5-/- mice
- Conditional knockouts: Region-specific deletion
- Transgenic models: Human DRD1 expression
The study of D1 Like Dopamine Receptor Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.